Home Science & Medicine Targeted Therapy

Targeted Therapy

Feature articles about advances and current developments in targeted therapy that have significant impact or impact potential on thoracic oncology.

ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell Lung Cancer

By Heather Wakelee, MD For most of the world, four cycles of cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage...

Clinical Labeling in Medicinal Products: An Interview With Dr. David Planchard About the Effects...

By David Planchard, MD, PhD What was the rationale for conducting clinical research in BRAF mutationpositive NSCLC? Recently, progress has been made in characterization of the...

The Lung Master Protocol (Lung-MAP)

By Vassiliki A. Papadimitrakopoulou, MD Lung-MAP (S1400), is a unique master multi-study protocol that incorporates genomic testing of tumors through a next-generation sequencing (NGS) platform...

Benefit of EGFR Mutation Analysis from Plasma Cell-Free DNA for Treatment of Advanced Non-Small...

By Tony S. K. Mok, BMSc, MD, FRCPC Patients must first be identified as having an epidermal growth factor receptor (EGFR) mutation before they can...

Osimertinib: A New Option in Non-Small Cell Lung Cancer – Q&A with David R....

By Erik J. MacLaren, PhD Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), received FDA approval in November 2015 for use...

Alectinib and ALK-Positive Non-Small Cell Lung Cancer – Q&A with Alice T. Shaw, MD,...

By Erik J. MacLaren, PhD Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that was recently approved in the US as a second- line...

Afatinib Outperforms Gefitinib in Advanced Non-Small Cell Lung Cancer

By Erik J. MacLaren, PhD The pan-ErbB inhibitor afatinib (Gilotrif) improves progression-free survival (PFS), time-to-treatment-failure (TTF) rate, and objective response rate (ORR) compared to the...

Meeting News